Editorial:
Mark Henderson, Editor
Whoever said that high-tech success is equal parts serendipity and business acumen could easily have been talking about Performance Plants (see page 3). The Kingston-based ag-biotech company has built a strong business case around a discovery that was stumbled upon by sheer happenstance.
Commercialization advocates work to get on next Conservative priority list
Promised fall economic agenda
There is cautious but growing optimism that the new Conservative administration is seriously considering adding innovation and commercialization to its next set of priorities leading into the critical fall decision-making process for the next federal Budget.
PARTEQ Innovations adds bridge loans to suite of commercialization services
PARTEQ Innovations, the not-for-profit tech transfer arm of Queen’s Univ, is launching a new service to assist its spinoff companies in managing fluctuations in cash flow. PARTEQ Treasury Services will provide short-term bridge loans to firms that require cash and agree to use their scientific research & experimental development (SR&ED) tax credits to secure the advances.
Provincial funding gives Genome BC flexibility to launch new projects
Genome BC is striking out on an ambitious five-year plan that could see up to $300 million invested in key areas of research and applications that correspond to the province’s emerging life sciences strategy.
Opinion Leader:
Ron Freedman
Ron Freedman
Getting to the next level
By Ron Freedman
Is Canada’s innovation system “maxed-out”? Has it reached some sort of natural limit? That is one conclusion that could be drawn from a new report on scientific publishing in Canada, CUP 20061.
Performance Plants secures $12 million in VC to achieve revenue sustainability
Kingston-based Performance Plants Inc has raised $12 million in the first tranche of an anticipated $15-million round of venture financing to move to revenue sustainability by 2009. The 11-year-old plant biotechnology firm secured the funding from a syndicate of venture capital firms to relocate off the Queen’s Univ campus into a new facility and ramp up product offerings based on its Value Enhanced Stress Tolerance (VEST) technologies – one of several technologies under development.
Student turnover and "institutional fog" stifle university-industry research collaborations
New Conference Board Report
Canada could produce greater results from public-private research collaborations by taking steps to reduce student turnover, clarify university rules and offer tax credits to companies that partner with universities, according to the Conference Board of Canada.
Distinguished UK researcher joins Genome Canada
Genome Canada has secured the services of a distinguished British researcher as its new chief scientific officer (CSO). Dr Michael Morgan comes to the agency from the UK where he has held a number of high-profile positions, including director of research partnerships and ventures with the Wellcome Trust, chief executive of the Wellcome trust Genome Campus in Cambridge and a major role in the international coordination of the Human Genome Project.